Welcome to the UPF Digital Repository

Evaluation of the host immune response assay SeptiCyte RAPID for potential triage of COVID-19 patients

Show simple item record

dc.contributor.author Montero, Maria Milagro
dc.contributor.author Hardy-Werbin, Max
dc.contributor.author Gonzalez-Gallardo, Soledad
dc.contributor.author Torres, Erica
dc.contributor.author Rueda, Rebeca
dc.contributor.author Arenas-Miras, María Del Mar
dc.contributor.author Arietta-Aldea, Itziar
dc.contributor.author Castañeda, Silvia
dc.contributor.author Gómez Junyent, Joan
dc.contributor.author Gómez-Zorrilla, Silvia
dc.contributor.author Guerri-Fernandez, Robert
dc.contributor.author Sánchez-Martínez, Francesca
dc.contributor.author López Montesinos, Inmaculada
dc.contributor.author Pelegrín, Iván
dc.contributor.author Sendra, Elena
dc.contributor.author Sorlí, Luisa
dc.contributor.author Villar García, Judit
dc.contributor.author Bellosillo Paricio, Beatriz
dc.contributor.author Horcajada Gallego, Juan Pablo
dc.date.accessioned 2023-02-08T07:24:01Z
dc.date.available 2023-02-08T07:24:01Z
dc.date.issued 2023
dc.identifier.citation Montero MM, Hardy-Werbin M, Gonzalez-Gallardo S, Torres E, Rueda R, Hannet I, et al. Evaluation of the host immune response assay SeptiCyte RAPID for potential triage of COVID-19 patients. Sci Rep. 2023 Jan 18;13(1):944. DOI: 10.1038/s41598-023-28178-y
dc.identifier.issn 2045-2322
dc.identifier.uri http://hdl.handle.net/10230/55674
dc.description.abstract Tools for the evaluation of COVID-19 severity would help clinicians with triage decisions, especially the decision whether to admit to ICU. The aim of this study was to evaluate SeptiCyte RAPID, a host immune response assay (Immunexpress, Seattle USA) as a triaging tool for COVID-19 patients requiring hospitalization and potentially ICU care. SeptiCyte RAPID employs a host gene expression signature consisting of the ratio of expression levels of two immune related mRNAs, PLA2G7 and PLAC8, measured from whole blood samples. Blood samples from 146 adult SARS-CoV-2 (+) patients were collected within 48 h of hospital admission in PAXgene blood RNA tubes at Hospital del Mar, Barcelona, Spain, between July 28th and December 1st, 2020. Data on demographics, vital signs, clinical chemistry parameters, radiology, interventions, and SeptiCyte RAPID were collected and analyzed with bioinformatics methods. The performance of SeptiCyte RAPID for COVID-19 severity assessment and ICU admission was evaluated, relative to the comparator of retrospective clinical assessment by the Hospital del Mar clinical care team. In conclusion, SeptiCyte RAPID was able to stratify COVID-19 cases according to clinical severity: critical vs. mild (AUC = 0.93, p < 0.0001), critical vs. moderate (AUC = 0.77, p = 0.002), severe vs. mild (AUC = 0.85, p = 0.0003), severe vs. moderate (AUC = 0.63, p = 0.05). This discrimination was significantly better (by AUC or p-value) than could be achieved by CRP, lactate, creatine, IL-6, or D-dimer. Some of the critical or severe cases had "early" blood draws (before ICU admission; n = 33). For these cases, when compared to moderate and mild cases not in ICU (n = 37), SeptiCyte RAPID had AUC = 0.78 (p = 0.00012). In conclusion, SeptiCyte RAPID was able to stratify COVID-19 cases according to clinical severity as defined by the WHO COVID-19 Clinical Management Living Guidance of January 25th, 2021. Measurements taken early (before a patient is considered for ICU admission) suggest that high SeptiScores could aid in predicting the need for later ICU admission.
dc.format.mimetype application/pdf
dc.language.iso eng
dc.publisher Nature Research
dc.relation.ispartof Sci Rep. 2023 Jan 18;13(1):944
dc.rights © The Author(s) 2023. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
dc.rights.uri http://creativecommons.org/licenses/by/4.0/
dc.title Evaluation of the host immune response assay SeptiCyte RAPID for potential triage of COVID-19 patients
dc.type info:eu-repo/semantics/article
dc.identifier.doi http://dx.doi.org/10.1038/s41598-023-28178-y
dc.subject.keyword Diagnostic markers
dc.subject.keyword Infectious-disease diagnostics
dc.subject.keyword Viral infection
dc.rights.accessRights info:eu-repo/semantics/openAccess
dc.type.version info:eu-repo/semantics/publishedVersion

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Advanced Search

Browse

My Account

Statistics

In collaboration with Compliant to Partaking